Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Hookipa Pharma Inc.
About
  2. Companies
  3. Hookipa Pharma Inc.
  4. Services
  5. Human Immunodeficiency Virus (HIV) ...

Human Immunodeficiency Virus (HIV) Therapy Services

SHARE

The objective of the Human Immunodeficiency Virus (HIV) program is to use HOOKIPA’s technologies to design arenavirus vectors (Lymphocytic Choriomeningitis Virus or Pichinde Virus based) suitable for treatment, cure or prevention of HIV. Together with our partner Gilead Sciences we intend to develop functional therapies for patients already infected with HIV.

Most popular related searches
human immunodeficiency virus HIV
human immunodeficiency virus
preclinical data
hiv therapy
immunodeficiency
clinical trial
hiv virus
hiv prevention
hiv infected
hiv infection

During 2019, HOOKIPA received $6.0 million in milestone payments from Gilead for the delivery of research vectors and advancing the programs closer to clinical trials. Based on preclinical data generated to date, Gilead committed to preparations to advance the HBV and HIV vectors toward development. To enable the development activities and expanded research programs, Gilead agreed to reserve manufacturing capacity and increase reimbursement budgeted for our expanded resources allocated to the Gilead collaboration.